Novartis' new heart failure drug to receive accelerated EU review

November 28, 2014 11:13 AM

15 0

Novartis has announced that its new heart failure drug LCZ696 is to benefit from an accelerated European review process.

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has granted accelerated assessment status to the investigational medicine, which is intended for patients with heart failure with reduced ejection fraction.

Read more

To category page